Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.96 USD | -1.31% | +1.01% | -31.24% |
May. 31 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
May. 24 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.24% | 5.04B | |
+0.99% | 91.72B | |
0.00% | 39.44B | |
-10.12% | 34.47B | |
+65.46% | 26.7B | |
-18.05% | 15.13B | |
-5.88% | 13.27B | |
-10.69% | 11.74B | |
-47.78% | 10.54B | |
+8.09% | 9.41B |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- Transcript : Apellis Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024